Biology • Year 12 • Module 7 • Lesson 18
Malaria and Dengue: Global Case Study
Build HSC Band 5–6 extended-response technique on vector-borne disease control — evaluating integrated strategies using real data and biological reasoning.
1. Scenario-based extended response — Wolbachia release in Yogyakarta (Band 5–6)
8 marks Band 5–6
Stimulus. In Yogyakarta, Indonesia, researchers from the World Mosquito Program conducted a randomised controlled trial (RCT) between 2017 and 2020. They released Aedes aegypti mosquitoes infected with Wolbachia bacteria into half of 24 randomised city clusters. Wolbachia bacteria compete intracellularly with dengue virus, dramatically reducing the mosquito's ability to replicate and transmit the virus — a property called reduced vector competence. The Wolbachia spreads naturally through subsequent generations of mosquitoes via cytoplasmic incompatibility (uninfected females mating with Wolbachia-infected males produce no viable offspring, favouring the Wolbachia strain).
Results: Dengue incidence in treated clusters was 77.1% lower than in untreated control clusters. Hospitalisation for dengue was 86.2% lower. These effects persisted throughout the follow-up period without additional releases.
Data table — dengue incidence in Yogyakarta trial clusters
| Cluster type | Dengue cases per 1,000 person-years | Hospitalisation rate (%) |
|---|---|---|
| Control (no Wolbachia) | 9.4 | 18.2 |
| Treated (Wolbachia released) | 2.2 | 2.5 |
Adapted from Utarini et al. (2021), New England Journal of Medicine, 384(23), 2179–2189.
Q1. Evaluate the use of Wolbachia release as a strategy for dengue control. In your response you must:
- Explain the biological mechanism by which Wolbachia reduces dengue transmission in Aedes aegypti.
- Analyse the Yogyakarta trial data: calculate the percentage reduction in dengue incidence and interpret what the hospitalisation data add to the picture.
- Compare the Wolbachia approach to two other dengue control strategies (from the lesson) on at least two criteria each (e.g. mechanism, sustainability, resistance risk, cost or community requirement).
- Assess a limitation of the Yogyakarta trial data and explain how it affects the strength of your conclusion.
- Reach a justified, evidence-based judgement about the overall value of Wolbachia release in an integrated dengue-control program.
2. Extended response — evaluating integrated malaria control (Band 5–6)
7 marks Band 5–6
Context. The lesson notes that between 2000 and 2015, malaria deaths in sub-Saharan Africa fell by approximately 58%, largely driven by scaled-up bed net distribution and ACT availability. Since 2015, progress has stalled. Insecticide resistance in Anopheles populations and artemisinin partial resistance in Plasmodium falciparum are identified as key factors. The WHO approved the R21/Matrix-M malaria vaccine in 2023 with reported efficacy of ~75–80% in children.
Australia's relevance: Australia eliminated local malaria transmission in the early 20th century through drainage of Anopheles breeding sites, DDT use, and prompt treatment of imported cases. Queensland and the Northern Territory remain climatically suitable for Anopheles mosquitoes, requiring ongoing surveillance to prevent re-establishment.
Q2. Analyse and evaluate why malaria control programs in sub-Saharan Africa achieved significant progress from 2000 to 2015, and assess why that progress has since stalled. In your response you must:
- Identify and explain two interventions responsible for the 2000–2015 decline, including their biological mechanisms.
- Explain, using the concept of natural selection, why both insecticide and drug resistance are now undermining those interventions.
- Assess the likely impact of the R21/Matrix-M vaccine on sub-Saharan African malaria burden, identifying at least one constraint on deployment.
- Use the Australian example to illustrate that elimination is biologically feasible when the right conditions are met.
- Reach an overall evaluative judgement: can malaria be eliminated from sub-Saharan Africa using existing tools? Justify your position.
Q1 — Sample Band 6 response (8 marks), annotated
Wolbachia reduces dengue transmission through a mechanism of reduced vector competence: when the bacterium infects Aedes aegypti cells, it competes intracellularly with dengue virus for cellular resources and activates immune pathways within the mosquito that suppress viral replication. The mosquito remains alive and reproducing, but can no longer replicate dengue virus to levels sufficient for transmission. [1 — mechanism correctly explained]
The Yogyakarta data show a reduction in dengue incidence from 9.4 to 2.2 cases per 1,000 person-years — a reduction of (9.4 − 2.2) / 9.4 × 100 = 76.6%, consistent with the stated 77.1% figure. The hospitalisation data are clinically significant: rates fell from 18.2% to 2.5%, meaning the Wolbachia intervention reduced not just infection frequency but also severe disease. This suggests that even breakthrough infections in the treated population may be less severe, possibly because reduced viral loads in the mosquito lead to lower inoculating doses in humans. [2 — calculation correct and hospitalisation data correctly interpreted beyond just confirming the incidence result]
Compared to vector breeding-site control (removing standing water): breeding-site control directly eliminates Aedes aegypti larvae before they mature into adults, whereas Wolbachia leaves the mosquito population intact and modifies its competence. Breeding-site control requires sustained community engagement and daily household action — compliance is a constant challenge in urban settings with high turnover. Wolbachia, by contrast, spreads autonomously through subsequent generations via cytoplasmic incompatibility once a threshold mosquito frequency is achieved, requiring no further human intervention after the initial release. However, breeding-site control can be applied anywhere immediately with no regulatory approval, while Wolbachia release requires regulatory permission and may face community acceptance barriers. [1 — comparison on at least two criteria]
Compared to GM mosquitoes (OX513A): OX513A males carry a self-limiting gene that causes offspring to die, progressively suppressing the Aedes aegypti population. Trials showed 70–90% population reduction. Unlike Wolbachia, OX513A requires continuous releases to maintain the effect — once releases stop, the wild-type population rebounds. Wolbachia is self-sustaining once established. However, OX513A suppresses the whole mosquito population (potentially useful against other Aedes-borne diseases), while Wolbachia maintains the mosquito population and reduces only its vector competence. Neither approach is likely to create insecticide resistance since neither uses insecticides. [1 — second comparison on at least two criteria]
A significant limitation of the Yogyakarta data is that the trial was conducted in a single urban setting in Indonesia — a high-dengue-incidence, moderate-income tropical city. Generalisability to rural settings, Pacific island communities, Latin American favelas, or sub-Saharan African cities (where different serotype distributions and mosquito population genetics exist) is uncertain. Additionally, the trial lasted three years; whether Wolbachia frequency is maintained and protective efficacy persists over decades of ecological change remains unknown. These limitations mean the 77% figure should be interpreted with caution when planning large-scale programs in different settings. [1 — limitation identified and its effect on the strength of the conclusion correctly explained]
Overall, Wolbachia release represents a highly promising addition to integrated dengue control: it is self-sustaining, carries no resistance risk (there is no selection pressure on the mosquito to develop resistance to Wolbachia in the same way that insecticides drive resistance), and produced the largest dengue-incidence reductions of any vector control trial to date. However, it is not a standalone solution — it does not address dengue serotype-immune complexity, cannot substitute for a broadly effective vaccine, and requires careful regulatory pathways. Its greatest value is within an integrated program combining breeding-site elimination, surveillance, and supportive clinical care. [2 — justified, evidence-based, nuanced judgement integrating all previous points]
Marking criteria (8 marks):
- 1 mark — Correctly explains the biological mechanism by which Wolbachia reduces dengue transmission (intracellular competition / reduced vector competence, not killing the mosquito).
- 1 mark — Correctly calculates the percentage reduction in dengue incidence from the table data (~77%).
- 1 mark — Interprets the hospitalisation data as a separate and additional finding (not just restating the incidence result).
- 1 mark — Compares Wolbachia to at least one other dengue control strategy (breeding-site control or GM mosquitoes) on at least two criteria.
- 1 mark — Compares Wolbachia to a second other dengue control strategy on at least two criteria.
- 1 mark — Identifies a specific limitation of the Yogyakarta trial data and explains how it affects the strength of the conclusion (not just "it's only one study").
- 1 mark — Reaches a justified evaluative judgement about the overall value of Wolbachia release.
- 1 mark — Response uses specific data values from the table (not just percentages from the stimulus text) and precise biological terminology throughout (vector competence, cytoplasmic incompatibility or equivalent, serotype, or equivalent terms).
Q2 — Sample Band 6 response (7 marks), annotated
Intervention 1 — Insecticide-treated bed nets (ITNs): Coverage in sub-Saharan Africa increased from approximately 2% to 65% of households between 2000 and 2015. ITNs prevent bites physically during sleeping hours (when nocturnal Anopheles feeds) and kill mosquitoes that land on the pyrethroid-coated net. Reducing the rate at which infected Anopheles deliver sporozoites into humans directly cuts both incidence and — because fewer gametocyte carriers exist — the reservoir available for mosquitoes to pick up. [1 — intervention correctly identified with mechanism]
Intervention 2 — Artemisinin combination therapy (ACT): ACT replaced older monotherapies as the first-line treatment for clinical malaria. It rapidly kills blood-stage Plasmodium parasites in red blood cells, dramatically shortening illness duration and reducing gametocyte production — thereby reducing the chance that a feeding mosquito acquires the parasite and continues the transmission cycle. ACT access was scaled up through the Global Fund programs from the mid-2000s. [1 — second intervention with mechanism]
Progress has stalled because natural selection is eroding both tools. In Anopheles populations, decades of exposure to pyrethroid insecticides (on nets and in IRS) have selected for individuals carrying resistance alleles — particularly mutations in voltage-gated sodium channel genes — that render pyrethroids ineffective. Mosquitoes that were once killed by landing on a treated net now survive and reproduce, passing resistance alleles to offspring. This is a direct application of natural selection: resistance alleles confer differential survival under selection pressure, increase in frequency across generations. Similarly, in Plasmodium falciparum populations in Southeast Asia (and increasingly Africa), mutations in the Kelch13 gene confer partial resistance to artemisinin, allowing parasites to survive standard treatment courses. ACT selection pressure has increased the frequency of these resistance alleles. [2 — natural selection correctly applied to both insecticide and drug resistance, with mechanism for each]
The R21/Matrix-M vaccine, with approximately 75–80% efficacy, offers a genuinely new tool. If deployed at scale — particularly to children under five, who bear 76% of malaria deaths — R21 could drive substantial mortality reductions that bed nets and ACT alone can no longer achieve. A key constraint is cold chain requirements: the vaccine must be stored at 2–8 °C throughout distribution to remote, hot, infrastructure-poor settings in sub-Saharan Africa, which requires significant investment in refrigeration. Healthcare system capacity to deliver four-dose schedules to young children in high-burden areas is also a limiting factor. [1 — R21 impact assessed with specific constraint correctly identified]
Australia eliminated local malaria transmission in the early 20th century through a combination of Anopheles breeding-site drainage (swamp drainage in coastal areas), targeted DDT use, and prompt treatment of imported cases — demonstrating that elimination is biologically feasible when political will, funding, and infrastructure exist. This is instructive: sub-Saharan Africa is not categorically unable to eliminate malaria by biological argument, but the scale, poverty, and healthcare infrastructure challenges are far greater. [1 — Australian example correctly used as a comparison]
Overall judgement: Elimination from sub-Saharan Africa using existing tools alone is not feasible in the near term. The 2000–2015 progress shows what scaled investment can achieve, but resistance to both primary tools, funding gaps, and geographic complexity mean that elimination would require R21 at scale, next-generation insecticides or alternative vector-control strategies (e.g. Wolbachia), and sustained political and financial commitment far beyond current levels. The tools exist to reduce burden dramatically; elimination requires a combination not yet fully deployed. [1 — overall evaluative judgement is conditional and evidence-based, not a binary "yes/no"]
Marking criteria (7 marks):
- 1 mark — Identifies and explains ITNs (or IRS) with correct biological mechanism.
- 1 mark — Identifies and explains ACT with correct biological mechanism.
- 1 mark — Explains insecticide resistance via natural selection with a named mechanism (allele selection, pyrethroid resistance channel mutations or equivalent).
- 1 mark — Explains artemisinin drug resistance via natural selection with a named mechanism (Kelch13 or equivalent; selection of resistant genotypes).
- 1 mark — Assesses R21 vaccine potential with at least one specific, correctly identified deployment constraint (cold chain, four-dose schedule, infrastructure).
- 1 mark — Uses the Australian case correctly as evidence that elimination is biologically achievable under the right conditions.
- 1 mark — Reaches a conditional, evidence-based evaluative judgement (not a bare "yes" or "no") about elimination feasibility, integrating resistance, new tools, and structural factors.